Christopher Moertel, MD, University of Minnesota, Minneapolis, MN, discusses the Phase IIb ReNeu trial (NCT03962543) evaluating mirdametinib in in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN). Mirdametinib showed a significant objective response rate (ORR), with deep and lasting reductions in PN volume, improvements in pain severity and interference, and enhanced health-related quality of life (HRQoL). Both adults and children benefited, with manageable safety profiles. These findings highlight mirdametinib’s potential as a treatment option for NF1 PN patients of all ages. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
